Phase III Multicenter Open-Label Randomized Trial to Evaluate Efficacy and Safety of CPI-613 in Combination with High Dose Cytarabine and Mitoxantrone (CHAM) Compared to High Dose Cytarabine and Mitoxantrone (HAM) in Older Patients (≥60 years) with Relapsed/Refractory Acute Myeloid Leukemia (AML)

IRB/UVA Tracking #
21391
Contact
Contact Phone
Phase
III
Primary purpose
Treatment
Cancer PI
Michael Keng
Status
OPEN TO ACCRUAL
Ages
Adult